The Simply Good Foods Company Nominates Joseph Schena to Join Board of Directors

DENVER, Dec. 10, 2020 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today announced that Joseph Schena has been nominated as an independent director for election at the Company’s January 21, 2021 Annual Meeting of Stockholders. As previously planned pursuant to the board’s mandatory retirement policy, Arvin “Rick” Kash will not stand for reelection at the 2021 Annual Meeting of Stockholders and his term will expire at the January meeting.

Mr. Schena, 62, is a consumer products industry executive with 40 years of experience in the areas of Financial Operations and Accounting, Strategy and Business Planning, Investor Relations and Mergers & Acquisitions. “Joe’s retail and consumer packaged goods background and experience, as well as his financial acumen, would make him a great addition to the Company’s board of directors,” said Joseph E. Scalzo, President and Chief Executive Officer of Simply Good Foods.

Mr. Schena had served as the Chief of Staff at Cohen Enterprises focused on C&S Wholesale Grocers and Warehouse Technologies from November 2015 until April 2019. Mr. Schena also served as a director of Warehouse Technologies until January 2020. Previously, Mr. Schena served as Chief Financial Officer and Executive Vice President at C&S Wholesale Grocers. Prior to joining Cohen Enterprises, Mr. Schena served as the Chief Executive Officer and President at Bacardi International Limited and as the Chief Financial Officer of Bacardi Limited. Mr. Schena was an Operating Partner at Centerview Capital Consumer from 2007 to 2012 focused on financial operations of portfolio companies. Prior to that, Mr. Schena held various senior financial and strategy positions at The Gillette Company, Nabisco Foods and Kraft General Foods. Additionally, Mr. Schena was previously a director of Conyers Park II Acquisition Corp. and Welsh Foods. Mr. Schena received an M.B.A. in Finance and a B.B.A. in Accounting from Iona College.

“Rick Kash has served on our board since July of 2017. His marketing and strategic capabilities made him a tremendous board member and he could always be counted on to provide valuable consumer insights,” said James M. Kilts, Chairman of the board of directors. “On behalf of Simply Good Foods’ senior management team and our entire board, we are grateful for Rick’s contributions and input over the last three and half years.”

About The Simply Good Foods Company

The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a highly-focused food company with a product portfolio consisting primarily of nutrition bars, ready-to-drink shakes, sweet and salty snacks and confectionery products marketed under the Atkins®, Quest®, and Atkins Endulge® brand names. Simply Good Foods is poised to expand its wellness platform through innovation and organic growth along with investment opportunities in the snacking space and broader food category. Simply Good Foods aims to lead the nutritious snacking movement with trusted brands that offer a variety of convenient, innovative, great-tasting, better-for-you snacks and meal replacements. For more information, please http://www.thesimplygoodfoodscompany.com.

Forward Looking Statements

Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by or include words such as “will”, “expect”, “intends” or other similar words, phrases or expressions. These forward-looking statements include the expected effects from the COVID-19 outbreak, statements regarding the integration of Quest, future plans for the Company, the estimated or anticipated future results and benefits of the Company’s future plans and operations, future capital structure, future opportunities for the Company, and other statements that are not historical facts. These statements are based on the current expectations of the Company’s management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties and the Company’s business and actual results may differ materially. These risks and uncertainties include, but are not limited to the effect of the COVID-19 outbreak on the Company’s business, suppliers (including its contract manufacturing and logistics suppliers), customers, consumers and employees along with disruptions or inefficiencies in the supply chain resulting from any effects of the COVID-19 outbreak; achieving the anticipated benefits of the Quest acquisition; difficulties and delays in achieving the synergies and cost savings in connection with the Quest acquisition; changes in the business environment in which the Company operates including general financial, economic, capital market, regulatory and political conditions affecting the Company and the industry in which the Company operates; changes in consumer preferences and purchasing habits; the Company’s ability to maintain adequate product inventory levels to timely supply customer orders; changes in taxes, tariffs, duties, governmental laws and regulations; the availability of or competition for other brands, assets or other opportunities for investment by the Company or to expand the Company’s business; competitive product and pricing activity; difficulties of managing growth profitably; the loss of one or more members of the Company’s or Quest’s management team; and other risk factors described from time to time in the Company’s Form 10-K, Form 10-Q, and Form 8-K reports (including all amendments to those reports) filed with the U.S. Securities and Exchange Commission from time to time. In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of future events and views as of the date of this communication. Except as required by law, the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, and cautions investors not to place undue reliance on any such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this communication.

Investor Contact

Mark Pogharian
Vice President, Investor Relations, Treasury and Business Development
The Simply Good Foods Company
(720) 768-2681
[email protected]



Climb Channel Solutions Adds Puppet’s Automation Platform to Distribution Line

EATONTOWN, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor, today announced a new distribution partnership with Puppet, the industry standard for infrastructure automation. By adding Puppet’s platform and solution to its offering, Climb will open up new opportunities for its customers, including the ability to scale DevOps, reduce risk, enforce policy as code, and manage and evolve cloud strategies, regardless of environment.

More than 40,000 companies, including 80 percent of Global 5,000, rely on Puppet’s technology for automating and orchestrating infrastructure and application delivery. Puppet’s platform integrates with your existing technology investments to uniquely standardize and scale varying IT environments. Puppet Enterprise Platform integrations and managed technologies makes sure all your key automation technologies work together, including Microsoft, Splunk, and more.

“As organizations expand their cloud strategies and scale their DevOps initiatives – they’re finding challenges in meeting security and compliance standards. Infrastructure stacks, tools and processes are getting more complicated, not less,” said Paul Heywood, Chief Revenue Officer at Puppet. “We couldn’t be more excited to partner with a distributor who knows the challenges of infrastructure, operations and development teams today. Puppet Enterprise Platform will help Climb’s customers speed up cloud strategies, scale DevOps initiatives and meet the most rigorous security and compliance standards – all alongside the key technologies already in their stack – to simplify the complexity of managing infrastructure at scale.”

“We’ve had an excellent experience with the Puppet Channel Sales team. I’m confident that they will become a foundational addition to our Software & Application Lifecycle suite of offerings,” said Dale Foster, CEO of Climb Channel Solutions.

Those interested in distribution services and solutions should contact Climb by phone at +1.800.847.7078 (US), or +1.888.523.7777 (Canada), or by email at [email protected].

About
Climb Channel Solutions

Climb Channel Solutions, a subsidiary of Wayside Technology Group, Inc. (NASDAQ: WSTG), is an international specialty technology distributor focused on emerging technologies. Climb provides partners with access to Security, Data Management, Virtualization and Cloud, Storage and Hyperconverged Infrastructure, Connectivity, Software and Application Lifecycle, and other technically sophisticated products. The company helps vendors recruit and build multinational solution provider networks, power their networks, and drive incremental sales revenues that complement existing sales channels. Climb services thousands of solution providers, VARs, systems integrators, corporate resellers, and consultants worldwide, helping them power a rich opportunity stream while building profitable businesses.

For additional information visit www.climbcs.com, or call 1.800.847.7078 (US), +1.732.389.0037
(International), +1.888.523.7777 (Canada), or +31.20.210.8005 (Europe).

Follow Climb Channel Solutions on Facebook, LinkedIn and Twitter.

 



Uxin to Report Second Quarter Fiscal Year 2021 Financial Results on December 17, 2020

BEIJING, Dec. 10, 2020 (GLOBE NEWSWIRE) — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), a leading nationwide online used car dealer in China, today announced that it will report its unaudited financial results for the second quarter of fiscal year 2021 ended September 30, 2020 before the open of U.S. markets on December 17, 2020.

Uxin’s management team will host a conference call on Thursday, December 17, 2020 at 8:00 a.m. U.S. Eastern Time (9:00 p.m. Beijing/Hong Kong time on the same day).

Due to the outbreak of COVID-19, operator assisted conference calls are not available at the moment. All participants must preregister online prior to the call to receive the dial-in details.

Conference Call
Preregistration

Participants can register for the conference call by navigating to http://apac.directeventreg.com/registration/event/1058883. Once preregistration has been completed, participants will receive dial-in numbers, an event passcode, and a unique registrant ID.

To join the conference, please dial the number you receive, enter the event passcode followed by your unique registrant ID, and you will be joined to the conference instantly.

A telephone replay of the call will be available after the conclusion of the conference call until December 24, 2020. The dial-in details for the replay are as follows:

U.S.: +1 646 254 3697
International: +61 2 8199 0299
Conference ID: 1058883

A live webcast and archive of the conference call will be available on the Investor Relations section of Uxin’s website at http://ir.xin.com/.

About
Uxin

Uxin Limited (Nasdaq: UXIN) is a leading nationwide online used car dealer in China. With its offerings of high-quality used cars and premium services, Uxin’s mission is to enable people to buy the car of their choice online. Uxin’s one-stop online shopping mall provides consumers with a nationwide selection of value-for-money used cars, various value-added products and services as well as comprehensive aftersales services. Its online sales consultants offer professional consulting to facilitate a convenient and efficient car purchase for consumers in a timely fashion. Its comprehensive fulfillment network supports nationwide logistics and delivery as well as title transfers between different cities across China so as to fulfill these online transactions.

For investor
and media
enquiries, please contact:

Nancy Song

Uxin Investor Relations
Tel: +86 10 5691 6765
Email: [email protected]

Eric Yuan

Christensen
Tel: +86 10 5900 1548
Email: [email protected]



Leading German Private Health Insurer Enters Contract to Provide ReWalk Exoskeletons to Individuals with Spinal Cord Injuries


Supply contract is the Company’s first with a private health insurer in Germany

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) — ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of robotic medical devices for people with lower extremity disabilities, today announced it has entered into a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury (SCIs) to apply for the procurement of a ReWalk 6.0 exoskeleton system.

The contractual agreement is the first such agreement with a private health insurer and follows a series of contracts with several statutory health insurance companies in Germany, which ReWalk signed earlier this year. Under the terms of this contract, eligible individuals can receive a ReWalk Personal 6.0 exoskeleton for everyday use after successful training, which can enable individuals with SCIs to stand and walk again.

“The ready adoption of supply contracts by public and private insurers across Germany supports exoskeleton devices for spinal cord injury becoming a standard of care for qualified beneficiaries,” said ReWalk CEO Larry Jasinski. “This new insurer is leading by example, and creating meaningful change in the lives of all those who will be able to procure a device and begin ReWalking in their communities.”

In 2018, the ReWalk 6.0 personal exoskeleton system was listed in the Medical Device Directory (MDD) of the National Association of Statutory Health Insurance Funds in Germany, which includes all approved devices for insurance procurement. That addition was a critical turning point that enabled any of Germany’s 105 statutory health insurance companies to pursue standards of care for ReWalk. After being listed in the MDD, ReWalk began to enter into supply contracts with a number of German insurers.


About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the United States, Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.


Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others
ReWalk’s management’s conclusion, and its independent registered public accounting firm’s statement in its opinion relating to its consolidated financial statements for the fiscal year ended December 31, 2019, that there is a substantial doubt as to the Company’s ability to continue as a going concern; the current COVID-19 pandemic has adversely affected and may continue to affect adversely business and results of operations; ReWalk’s ability to have sufficient funds to meet certain future capital requirements, which could impair the Company’s efforts to develop and commercialize existing and new products; ReWalk’s ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s ability to establish a pathway to commercialize its products in China; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk’s ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; ReWalk’s compliance with medical device reporting regulations to report adverse events involving the Company’s products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to its mandatory 522
postmarket
surveillance study; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company’s IT systems significantly disrupting its business operations; the impact of substantial sales of the Company’s shares by certain shareholders on the market price of the Company’s ordinary shares; ReWalk’s ability to use effectively the proceeds of its offerings of securities; the risk of substantial dilution resulting from the periodic issuances of ReWalk’s ordinary shares; the impact of the market price of the Company’s ordinary shares on the determination of whether it is a passive foreign investment company; and other factors discussed under the heading “Risk
Factors” in ReWalk’s annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. 

Investor Contact:

Ori Gon
Chief Financial Officer
ReWalk Robotics Ltd.
T: +972-4-9590123
E: [email protected] 



Aleafia Health to Enter Israeli Cannabis Market, Bolstering International Sales Opportunity

  • Three-year agreement signed with Equinox International
  • Shipments expected to commence in Q1 2021, marking Aleafia’s fourth country with products in market
  • Israel is largest net importer of medical cannabis globally

TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it will commence cannabis exports to the Israeli medical cannabis market. The Company signed a binding letter of intent (the “LOI”) with Equinox International Ltd., a licensed British medical cannabis company with operations in the Israeli market.

Under the LOI, Equinox has committed to purchasing approximately 1,400 kg of dried flower in 2021. The first shipment to Equinox is expected to occur in Q1 2021 pending receipt of necessary import and export permits and completion of Aleafia’s cultivation cycle. Permit applications have already been submitted and will mark the first export of EU GACP-compliant dried flower grown at Aleafia’s Niagara Greenhouse facility.

Israel, the world’s fastest growing medical cannabis market, reached over 60,000 registered patients in 2020, from half that figure in 2018. It is also the largest net importer of cannabis globally, recently surpassing Germany.

Equinox International, in partnership with Aleafia Health, will establish an Israeli Land-to-Brand ecosystem covering supply, distribution, market leading brands and retail.

“Gaining market access to Israel, an incredibly dynamic country with a fast growing, highly innovative cannabis market, is something we’ve long aspired to,” said Aleafia Health CEO Geoffrey Benic. “Doing so with Equinox, an accomplished, internationally scaled partner, marks an exciting chapter as we commercialize Aleafia Health globally.”

“Equinox is delighted to form a Land-to-Brand strategic partnership with Aleafia Health,” said Equinox International CEO Xan Morgan. “Equinox is firmly positioned as a British champion and in partnership with Aleafia will be a leader in the Israeli cannabis market.”

The parties must now negotiate a definitive agreement concerning the supply of dried flower to Israel over a three-year term. They have agreed to negotiate the definitive agreement exclusively with one another for a period of 45 days.

The parties shall negotiate and include in the definitive agreement additional minimum purchase commitments for the second and third years of the contract. For the duration of the definitive agreement and in respect of the Israeli market, Aleafia shall be Equinox’s sole supplier of cannabis products and Equinox shall be Aleafia’s sole purchaser of cannabis products.

Aleafia Health Contact:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
[email protected]
LEARN MORE: www.AleafiaHealth.com

Equinox International Contact:

Louise Freestone
+44 203-588-1007
[email protected]
LEARN MORE: www.EquinoxInternational.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

About Equinox International

Equinox is a Land to Brand British cannabis company investing in the development of licensed cannabis facilities and partnerships around the world, including proprietary formulations and genetics, as well as two British Champion brands. By combining extensive knowledge of the cannabis industry with scientific expertise and diverse business experience, Equinox aims to become a leading global cannabis supplier and a mark of quality around the world.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.



Decentralized Trials & Research Alliance (DTRA) Launches to Democratize and Accelerate Clinical Trials


New Global Industry Coalition Aims to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) — A historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

“The benefits of decentralized research methodologies have been apparent for some time, but adoption has been slow due to many factors including culture and the lack of a forum for stakeholders to collaborate,” said Amir Kalali, MD, life science executive, founder of several collaborative life science communities, and co-convenor of DTRA. “The COVID-19 pandemic has forced organizations to adopt decentralized methodologies which have the potential to broadly accelerate drug development.”

Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age, and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders we can remove remaining barriers to adopting new policies and practices that can impact patients today.”

“Equal access to clinical trials is the foundation of Stand Up To Cancer’s Health Equity Initiative and supports our mission to make every cancer patient a long-term survivor,” said Sung Poblete, CEO of Stand Up To Cancer. “SU2C and DTRA’s efforts are aligned in the goal of making it possible for any patient, anywhere, to access trials with convenience and safety, during the pandemic and beyond.”

DTRA Member organizations will provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. Organizations interested in taking part can visit DTRA.org

ABOUT DTRA:


The Decentralized Trials & Research Alliance (




DTRA




)

was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation acces
sible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on


Twitter


and


LinkedIn


for more information.

For further information please contact:

Media Contact:
Glenn Silver
Lazar – Finn Partners
[email protected]
646 871 8485

For Non-media Inquiries:

DTRA Secretariat
[email protected]
619-209-7371 



Lee Enterprises posts strong quarter and fiscal year results

Revenue trends improved 7.8 percentage points compared to third quarter
Subscription revenue totaled 46.5% of total operating revenue
2020 Debt reduction totaled $37.7 million since March refinancing
Implemented $84 million in Cost Synergies in 2020

DAVENPORT, Iowa, Dec. 10, 2020 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NYSE: LEE), a leading provider of high quality, trusted, local news, information and a major digital and subscription platform in 77 markets, today reported fourth quarter and year-to-date financial results(1) for the period ended September 27, 2020.

Financial Highlights(2):

  Fourth Quarter
2020
  Fiscal Year
2020
  Fiscal Year
2020
(i
n
Thousands)

Actual   Actual   Pro forma
           
Income (loss) attributable to Lee Enterprises, Incorporated (1,784 ) (3,106 ) 17,632
Adjusted EBITDA (3) 25,374   97,171   122,334

“We made significant progress toward our digital transformation and are pleased with the operating results in the fourth quarter. Digital services revenue through TownNews and subscription revenue make up nearly half of our total operating revenue and these revenue streams performed well in the fourth quarter. Digital-only subscriptions increased 67.3% over prior year quarter and now total 244,000, with revenue from digital-only subscribers up 71.4%. TownNews revenue grew 7.0% in the quarter, marking more than 10 years of consecutive quarter-over-quarter revenue growth. We expect these sticky revenue streams to continue strong performance in 2021,” said Kevin Mowbray, President and Chief Executive Officer.

“Also key to our performance was our keen focus on supporting our local advertisers through this disruption. Our stimulus programs and full service digital marketing agency, Amplified, helped to drive strong performance in advertising revenue. Though down quarter-over-quarter on a pro forma basis, our advertising revenue trend improved 13 percentage points in the fourth quarter compared to the quarter over quarter trends in the third quarter. Our total revenue trend on a pro forma basis also improved in the fourth quarter and, though down 16.9% in the fourth quarter, was 7.8 percentage points better than third quarter trend,” said Mowbray.

“We continue to see improvement in our core advertising trends in the first quarter with significant wins in political advertising. We remain committed to providing high quality, trusted local news that’s vital to our local markets covering critical issues that our large, local audiences depend on more than ever,” Mowbray added.

“Our significant acquisition of BH Media Group(4) in March 2020, combined with a global pandemic, provided an opportunity to accelerate our transformation. We have made significant progress on our business transformation and have implemented $84 million of cost reductions to date, ahead of our acquisition targets. Our strategy heading into 2021 is clear, and we are laser-focused on transforming the way we present local news and information, transforming our audience model to a robust subscription model and diversifying the service and products we offer our top local accounts and SMBs. We are optimistic that we will emerge from the pandemic a stronger, leaner organization focused on executing our digital transformation,” Mowbray said.

Tim Millage, Vice President, Chief Financial Officer and Treasurer, said “As a reminder, we executed a transformational refinancing(5) in 2020 that lowered our cost of debt and extended our maturities until 2045. The financing has no fixed mandatory principal payments and does not contain financial performance covenants. The principal amount of debt outstanding as of the end of the year totaled $538.3 million, or down $37.7 million from the refinancing in March,” Millage added.

Fourth Quarter Highlights(1):

  • Total digital revenue, including digital advertising, digital subscription revenue and digital services, was $47.9 million and represented 25% of our operating revenue.
  • Revenue at TownNews increased 7.0% in the fourth quarter and revenue over the last twelve months totaled $25.0 million.
  • Subscription revenue totaled $89.3 million, or 46.5% of the Company’s total operating revenue. Digital-only subscribers increased 13.5% and now total 244,000.
  • On a GAAP basis, total operating revenues were $191.8 million in the fourth quarter, compared to $123.7 million in the prior year quarter. On a pro forma basis, total operating revenue was down 16.9% in the quarter.
  • Operating expenses totaled $185.0 million and Cash Costs (3) on a pro forma basis were down 14.7%.
  • Net loss totaled $1.3 million and Adjusted EBITDA totaled $25.4 million.

Fiscal Year 2020 Financial Highlights(1):

  • Closed the compelling and transformative transaction with Berkshire Hathaway to acquire 31 local daily news publications, nearly doubling our audience size and refinancing all long-term debt on attractive terms.
  • Total revenue was $618.0 million in the fiscal year compared to $509.9 million in the prior year. On a pro forma basis, total operating revenue totaled $821.8 million in the fiscal year.
  • Total digital revenue was $164.3 million and increased 13.5% in fiscal year 2020 due to revenue increases, in advertising, subscription and digital services.
  • Net loss totaled $1.3 million and Adjusted EBITDA on a pro forma basis totaled $122.3 million.
  • Debt totaled $538.3 million at the end of 2020, a $37.7 million reduction since the refinancing in March.

DEBT AND FREE CASH FLOW

On March 16, 2020, the Company closed on the comprehensive refinancing of all of its outstanding debt. The $576 million in financing has a fixed annual interest rate of 9.0%, mandatory payments based on the Company’s Excess Cash Flow (4), no financial performance covenants and a 25-year maturity.

As of the 52 weeks ended September 27, 2020:

  • Principal amount of debt outstanding totaled $538.3 million.
  • Cash on the balance sheet totaled $33.7 million.
  • Excess Cash Flow for the fourth quarter totaled $13.7 million and was used to repay debt in the first quarter of 2021.
  • Capital expenditures totaled $8.7 million.
  • Pension contributions totaled $6.2 million in the quarter.

CONFERENCE CALL INFORMATION

As previously announced, we will hold an earnings conference call and audio webcast today at 9 a.m. Central Time. The live webcast will be accessible at www.lee.net and will be available for replay two hours later. Several analysts have been invited to ask questions on the call. Questions from other participants may be submitted by participating in the webcast. The call also may be monitored on a listen-only conference line by dialing (toll free) 800-309-1256 and entering a conference passcode of 473583 at least five minutes before the scheduled start. Participants on the listen-only line will not have the opportunity to ask questions.

ABOUT LEE

Lee Enterprises is a leading provider of local news and information, and a major platform for advertising, with daily newspapers, rapidly growing digital products and over 350 weekly and specialty publications serving 77 markets in 26 states. Year to date, Lee’s newspapers have average daily circulation of 1.2 million, and our legacy websites, including acquisitions, reach more than 43 million digital unique visitors. Lee’s markets include St. Louis, MO; Buffalo, NY; Omaha, NE; Richmond, VA; Lincoln, NE; Madison, WI; Davenport, IA; and Tucson, AZ. Lee Common Stock is traded on the New York Stock Exchange under the symbol LEE. For more information about Lee, please visit www.lee.net.

FORWARD-LOOKING STATEMENTS — The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This release contains information that may be deemed forward-looking that is based largely on our current expectations, and is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those anticipated. Among such risks, trends and other uncertainties, which in some instances are beyond our control, are:

  • Revenues may continue to diminish or declines in revenue could accelerate as a results of the COVID-19 pandemic;
  • Revenues may continue to be diminished longer than anticipated as a result of the COVID-19 pandemic;
  • The COVID-19 pandemic may result in material long-term changes to the publishing industry which may result in permanent revenue reductions for the Company and other risks and uncertainties;
  • We may experience increased costs, inefficiencies and other disruptions as a result of the COVID-19 pandemic;
  • We may be required to indemnify the previous owners of BH Media or Buffalo for unknown legal and other matters that may arise;
  • Our ability to manage declining print revenue and circulation subscribers;
  • That the warrants issued in our 2014 refinancing will not be exercised;
  • The impact and duration of adverse conditions in certain aspects of the economy affecting our business;
  • Changes in advertising and subscription demand;
  • Changes in technology that impact our ability to deliver digital advertising;
  • Potential changes in newsprint, other commodities and energy costs;
  • Interest rates;
  • Labor costs;
  • Significant cyber security breaches or failure of our information technology systems;
  • Our ability to achieve planned expense reductions and realize the expected benefit of our acquisitions;
  • Our ability to maintain employee and customer relationships;
  • Our ability to manage increased capital costs;
  • Our ability to maintain our listing status on the NYSE;
  • Competition; and
  • Other risks detailed from time to time in our publicly filed documents.

Any statements that are not statements of historical fact (including statements containing the words “may”, “will”, “would”, “could”, “believes”, “expects”, “anticipates”, “intends”, “plans”, “projects”, “considers” and similar expressions) generally should be considered forward-looking statements. Statements regarding our plans, strategies, prospects and expectations regarding our business and industry, including statements regarding the impacts that COVID-19 pandemic and our responses thereto may have on our future operations, are forward-looking statements. They reflect our expectations, are not guarantees of performance and speak only as of the date the statement is made. Readers are cautioned not to place undue reliance on such forward-looking statements, which are made as of the date of this release. We do not undertake to publicly update or revise our forward-looking statements, except as required by law.

Contact:
[email protected]
(563) 383-2100

CONSOLIDATE
D
STATEMENT
S
O
F
OPERATIONS

(UNAUDITED)

(Thousands
of
Dollars,
Except
Per
Share

Data)

13 Weeks
Ended
September 27
2020
  13 Weeks
Ended
September 29
2019
 

Percent
Change

  52 Weeks
Ended
September 27
2020
  52 Weeks
Ended
September 29
2019
 

Percent
Change

 
             
Advertising and marketing services 85,229   61,282   39.1   289,655   265,933   8.9  
Subscription 89,284   48,726   83.2   265,939   186,691   42.4  
Other 17,253   13,657   26.3   62,410   57,230   9.1  
Total operating revenue 191,766   123,665   55.1   618,004   509,854   21.2  
Operating expenses:
Compensation 78,693   42,672   84.4   243,023   182,869   32.9  
Newsprint and ink 7,614   4,843   57.2   24,243   22,237   9.0  
Other operating expenses 80,637   47,793   68.7   259,382   193,709   33.9  
Cash costs 166,944   95,308   75.2   526,648   398,815   32.1  
Total operating revenue less cash costs 24,822   28,357   (12.5 ) 91,356   111,039   (17.7 )
Depreciation and amortization 10,937   7,069   54.7   36,133   29,332   23.2  
Assets loss (gain) on sales, impairments and other, net (250 ) 2,676   NM   (5,403 ) 2,464   NM  
Restructuring costs and other 7,329   6,022   21.7   13,751   11,635   18.2  
Operating expenses 184,960   111,075   66.5   571,129   442,246   29.1  
Equity in earnings of associated companies (370 ) 1,823   NM   3,403   7,121   (52.2 )
Operating income 6,436   14,413   (55.3 ) 50,278   74,729   (32.7 )
Non-operating income (expense):
Interest expense (12,366 ) (11,232 ) 10.1   (47,743 ) (47,488 ) 0.5  
Debt financing and administrative costs (101 ) (1,160 ) (91.3 ) (11,966 ) (7,214 ) 65.9  
Other, net 8,965   1,082   NM   12,274   3,813   NM  
Non-operating expenses, net (3,502 ) (11,310 ) (69.0 ) (47,435 ) (50,889 ) (6.8 )
Income before income taxes 2,934   3,103   (5.4 ) 2,843   23,840   (88.1 )
Income tax expense (benefit) 4,195   1,758   NM   4,104   7,931   (48.3 )
Net income (1,261 ) 1,345   NM   (1,261 ) 15,909   NM  
Net income attributable to non-controlling interests (523 ) (526 ) (0.6 ) (1,845 ) (1,641 ) 12.4  
Income attributable to Lee Enterprises, Incorporated (1,784 ) 819   NM   (3,106 ) 14,268   NM  
             
Earnings per common share:
Basic (0.03 ) 0.01   NM   (0.05 ) 0.26   NM  
Diluted (0.03 ) 0.01   NM   (0.05 ) 0.25   NM  
   



RECONCILIATIO
N
O
F
NON-GAA
P
FINANCIA
L
MEASURES

(UNAUDITED)

The table below reconciles the non-GAAP financial performance measure of Adjusted EBITDA to net income, its most directly comparable GAAP measure:


(Thousands
of
Dollars)
13 Weeks
Ended
September 27
2020
  13 Weeks
Ended
September 29
2019
  52 Weeks
Ended
September 27
2020
  52 Weeks
Ended
September 29
2019
 
         
Net Income (1,261 ) 1,345   (1,261 ) 15,909  
Adjusted to exclude
Income tax expense (benefit) 4,195   1,758   4,104   7,931  
Non-operating expenses (income), net 3,502   11,310   47,435   50,889  
Equity in earnings of TNI and MNI 370   (1,823 ) (3,403 ) (7,121 )
Loss (gain) on sale of assets and other, net (250 ) 2,676   (5,403 ) 2,464  
Depreciation and amortization 10,937   7,069   36,133   29,332  
Restructuring costs and other 7,329   6,022   13,751   11,635  
Stock compensation 252   428   1,051   1,638  
Add:
Ownership share of TNI and MNI EBITDA (50%) (6) 300   2,325   4,764   8,811  
Adjusted EBITDA 25,374   31,110   97,171   121,488  

NOTES

(1) This earnings release is a preliminary report of results for the periods included. The reader should refer to the Company’s most recent reports on Form 10-Q and on Form 10-K for definitive information.

(2) Due to the material acquisition, our basis of presentation includes (i) our actual GAAP results, which reflect a full quarter of Lee Legacy(4), BHMG(4) and Buffalo(4) and year to date period of Legacy Lee and 28 weeks of results of BHMG and Buffalo, (ii) pro forma results, which reflect the consolidated operations, adjusted as if Lee had owned BHMG and Buffalo for the entire period presented, and (iii) Adjusted EBITDA(3), which is our non-GAAP measure of operating results, calculated based on actual results (with 28 weeks included in the 52 weeks ended September 27, 2020) and on a pro forma basis (assuming BHMG and Buffalo were owned for the entire period).

(3) The following are non-GAAP (Generally Accepted Accounting Principles) financial measures for which reconciliations to relevant GAAP measures are included in tables accompanying this release:

  • Adjuste
    d
    EBITD
    A is a non-GAAP financial performance measure that enhances financial statement users overall understanding of the operating performance of the Company. The measure isolates unusual, infrequent or non-cash transactions from the operating performance of the business. This allows users to easily compare operating performance among various fiscal periods and how management measures the performance of the business. This measure also provides users with a benchmark that can be used when forecasting future operating performance of the Company that excludes unusual, nonrecurring or one time transactions. Adjusted EBITDA is also a component of the calculation used by stockholders and analysts to determine the value of our business when using the market approach, which applies a market multiple to financial metrics. It is also a measure used to calculate the leverage ratio of the Company, which is a key financial ratio monitored and used by the Company and its investors. Adjusted EBITDA is defined as net income (loss), plus nonoperating expenses, income tax expense (benefit), depreciation and amortization, assets loss (gain) on sales, impairments and other, restructuring costs and other, stock compensation and our 50% share of EBITDA from TNI and MNI, minus equity in earnings of TNI and MNI and curtailment gains.

  • Cas
    h
    Cost
    s represent a non-GAAP financial performance measure of operating expenses which are measured on an accrual basis and settled in cash. This measure is useful to investors in understanding the components of the Company’s cash-settled operating costs. Generally, the Company provides forward-looking guidance of Cash Costs, which can be used by financial statement users to assess the Company’s ability to manage and control its operating cost structure. Cash Costs are defined as compensation, newsprint and ink and other operating expenses. Depreciation and amortization, assets loss (gain) on sales, impairments and other, other non-cash operating expenses and other expenses are excluded. Cash Costs also exclude restructuring costs and other, which are typically paid in cash.

(4) On March 16, 2020 (the Closing Date), the Company closed the acquisition of the newspaper assets of BH Media Group (“BH Media”) and the stock of The Buffalo News, Inc. (“Buffalo”). Legacy Lee refers to the operating assets and results of operations of the Company prior to the Closing Date, and is synonymous with same store results.

(5) The Company’s debt is the $576 million term loan under a credit agreement with BH Finance LLC dated January 29, 2020 (the “Credit Agreement”). Excess Cash Flow is defined under the Credit Agreement as any cash greater than $20,000,000 on the balance sheet in accordance with GAAP at the end of each fiscal quarter, beginning with the quarter ending June 28, 2020.

(6) TNI refers to TNI Partners publishing operations in Tucson, AZ. MNI refers to Madison Newspapers, Inc. publishing operations in Madison, WI.



MediPharm Labs Announces Leadership Changes

BARRIE, Ontario, Dec. 10, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, today announced a senior leadership transition.

To prepare the Company for its next phase of growth and to drive cost savings and efficiency improvements, MediPharm Labs announced the following changes, effective immediately in its senior leadership structure as well as roles and responsibilities:

  • Pat McCutcheon will step down as Chief Executive Officer but retain his role as Chairman of the Board
  • Keith Strachan will assume the role of Interim Chief Executive Officer
  • Warren Everitt will continue as Chief Executive Officer, Asia Pacific
  • Olga Utkutug appointed Interim Chief Financial Officer effective December 8, 2020
  • The Company will also immediately begin a process to search for a permanent Chief Executive Officer. A search for a new Chief Financial Officer is already underway.

“The time has come to move beyond our start-up structure and put in place the best people to execute our strategy and guide the way to better financial performance including our return to profitability,” said Mr. McCutcheon. “Keith and Warren have been instrumental to the growth of MediPharm. They will continue to be aligned on executing our large pipeline of domestic and international growth contracts in hand as well as new opportunities in Canada, Europe and Asia Pacific. We are in a tremendous position to realize global market share with our two GMP platforms. As Chairman, I look forward to working with the Board in the search for our new CFO and a permanent CEO while supporting Keith and Warren and driving forward our strategic growth initiatives.”

“MediPharm Labs has a strong foundation, excellent customer relationships, differentiated capabilities and a great future,” said Keith Strachan. “We have a clear mandate from the Board to step up the pace of our growth while keeping a tight grip on expenses to create shareholder value.”

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was established in 2017.   

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, growth; cost savings; efficiency improvements; the creation of shareholder value; the appointment of a new Chief Financial Officer and search for a permanent CEO, better financial performance and returning to profitability, new opportunities for the Company in Canada, Europe and Asia-Pacific, and the Company’s positioning to realize global market share. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.



For further information, please contact: 
Laura Lepore, VP, Investor Relations 
Telephone: +1 416.913.7425 ext. 1525
Email: [email protected]      
Website: www.medipharmlabs.com 

Skanska Celebrates Topping Out of Sixth South

The Beach Company’s 299-unit multifamily rental community in Nashville’s booming SoBro downtown neighborhood is ahead of schedule for a Fourth Quarter 2021 opening

Nashville, Tennessee, Dec. 10, 2020 (GLOBE NEWSWIRE) — Nashville, Tenn. (December 10, 2020) – Skanska, one of the world’s leading construction and development firms, announced today its topping out of the Sixth South, a 299-unit multifamily rental community within the downtown core of Nashville.

The 12-story building was topped out ahead of schedule, on pace for a fourth quarter 2021 opening. “We are proud to celebrate the Sixth South residential apartment building topping out ahead of schedule. Located in the SoBro district, our team is proud to contribute to the neighborhood’s continual growth and redevelopment,” said Dennis Georgatos, executive vice president and general manager for Skanska’s building operations in Tennessee.

Located between Peabody Street and Lea Avenue, the project is on the south side of Nashville’s growing SoBro neighborhood, an up and coming area of Nashville. As downtown continues to expand, the apartment inventory is much needed to accommodate the city’s growth.

In addition to the 299-units, the project will include 5,400 square feet of complementary commercial space and a parking garage. A complete amenity package for residents will include a clubroom, pet spa, fitness center, and rooftop saltwater pool. The architectural plan will maximize the views of downtown Nashville and Gulch skylines.

In reaching the topping out milestone, Skanska has poured more than 17,000 cubic yards of concrete, 650,000 square feet of formed surface, 480,000 square feet of troweled surface, as well as placed 900 tons of reinforcement bar and 730,000 pounds of post tension cable. This was achieved with the help of more than 380 individuals and approximately 122,000-work hours.

For more information on Skanska USA, visit: www.usa.skanska.com.



Elizabeth Locke
Skanska USA
214-763-5255
[email protected]

Long-Term Partners Greenlane and PAX LABS™ Renew Exclusive U.S. Distribution Agreement

Partners since 2012, Greenlane and PAX Labs continue their strategic collaboration

BOCA RATON, Fla., Dec. 10, 2020 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or “the Company”) (Nasdaq: GNLN), a global house of brands and one of the largest sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced that it has renewed its exclusive distribution partnership with PAX Labs™, a leading consumer technology brand in cannabis. The agreement maintains Greenlane’s exclusive distribution of all PAX® devices throughout the U.S.

PAX Labs is a global market leader in producing high-quality dry herb vaporizers, including the best-in-class PAX 3™ and PAX ERA PRO™. PAX’s world-class hardware and software teams create tools that allow consumers to personalize every experience through the PAX App, from temperature and dose control, to unprecedented access to information, including cannabinoid profiles and lab testing results. Based in San Francisco, PAX is determined to establish cannabis as a force for good.

“PAX Labs has been an influential partner throughout the past eight years since our initial distribution agreement. We’re honored to work alongside such a forward-thinking and like-minded brand as we continue to help bring their revolutionary vaporizers to market,” said Aaron LoCascio, Co-Founder and CEO of Greenlane.

“We highly value our relationship with Greenlane and are thrilled to continue working together to bring our technology and devices to new customers, and expand brand awareness in both adult use and medical markets,” added Dominic O’Brien, Chief Revenue Officer at PAX Labs. “As we enter the next phase of this partnership, we are confident in Greenlane’s ability to support our ambitious growth and mission to deliver premium cannabis experiences to consumers.”

Greenlane will continue to distribute all PAX devices through its vast distribution network of over 11,000 retail locations, including licensed cannabis dispensaries and headshops. Greenlane will leverage its network to distribute PAX Labs’ recently launched color refresh for its award-winning PAX 3™ vaporizer, designed for the modern, sophisticated consumer. The dry herb and concentrate vaporizer maximizes material efficiency and delivers smooth and smokeless vapor through gentle heating. With four temperature settings and +/- 1° temperature control, consumers can adjust the temperature to manage both flavor and vapor output through the PAX App. To shop PAX devices, visit wholesale.gnln.com.

About Greenlane Holdings, Inc.

Greenlane (NASDAQ: GNLN) is the leading global platform for the development and distribution of premium cannabis accessories and lifestyle products. The company operates as a powerful house of brands, a third-party brand accelerator, and omni-channel distribution platform. Greenlane serves the global markets with an expansive customer base of more than 11,000 retail locations, including licensed cannabis businesses, smoke shops, and specialty retailers. Greenlane’s world-class team provides services including product development, go-to-market strategy, sales and marketing support, customer service, direct-to-consumer fulfillment, supply chain management, and distribution. As a pioneer in the cannabis space, Greenlane is the partner of choice for many of the industry’s leading brands, including PAX Labs, Storz & Bickel (Canopy-owned), Cookies, Grenco Science, and DaVinci. Greenlane also proudly owns and operates a diverse brand portfolio including packaging innovator Pollen Gear™, the K.Haring Glass Collection by Higher Standards, Marley Natural™, and VIBES™ rolling papers. Higher Standards, Greenlane’s flagship brand, offers both a high-end product line and immersive retail experience with groundbreaking stores in both New York City’s Chelsea Market and Malibu, California. Greenlane also owns and operates both Vapor.com and VapoShop.com, two industry-leading, direct-to-consumer e-commerce platforms in North America and Europe respectively. For additional information, please visit: https://gnln.com/.

About PAX

Headquartered in San Francisco, PAX Labs™ is the leader in premium cannabis vaporizer technology, with award-winning devices for both concentrates and dry herb. Counting over 2 million devices sold, PAX Labs has revolutionized the consumer experience through innovation and product design that takes the guesswork out of cannabis and delivers quality, safety, and predictability. PAX Labs is committed to its mission of establishing cannabis as a force for good. PAX Labs does not manufacture, produce or sell cannabis and its products are not for sale to minors. For more information, visit pax.com.

For more informatio
n about Greenlane:

Media Contact

MATTIO Communications
[email protected] 

Investor Contact

Rob Kelly
Investor Relations, MATTIO Communications
[email protected] 
1-416-992-4539